Elsevier

European Urology

Volume 46, Issue 2, August 2004, Pages 235-240
European Urology

The Effect of Tamsulosin on the Resting Tone and the Contractile Behaviour of the Female Urethra: A Functional Urodynamic Study in Healthy Women

https://doi.org/10.1016/j.eururo.2004.04.009Get rights and content

Abstract

Aims: The aim of this functional urodynamic experiment was to study the effect of the selective α1A-blocker tamsulosin on the urethral pressure in healthy human females and assessed first the resting urethral pressure and second the urethral contractility in response to magnetic stimulation of the sacral roots.

Methods: 11 healthy female subjects gave their written informed consent and were included. A microtip pressure transducer catheter was inserted into the bladder and three baseline urethral pressure profiles were obtained. Another three urethral pressure profiles were recorded while magnetic single pulse stimulation of the sacral roots was performed above the motor threshold of the pelvic floor to evoke reproducible urethral contractions. Then the subjects received 0.4 mg of tamsulosin and the entire protocol was repeated 6 hours after drug administration. Cardiovascular monitoring was obtained during the baseline and follow-up measurements. Mean and maximal urethral pressure values calculated over the entire urethra, mean pressure values calculated over the proximal, middle and distal third of the urethra and the pressure amplitudes to magnetic stimulation at baseline were statistically compared to the follow-up measurements with tamsulosin.

Results: The oral administration of tamsulosin did not change the systemic blood pressure, but did significantly reduce the mean and maximal urethral pressure acquired over the entire urethra. When the proximal, middle and distal third of the urethra were analysed separately, there was a significant pressure reduction in all three segments. Amplitudes of the urethral contractions evoked by sacral magnetic stimulation remained unchanged after tamsulosin.

Conclusions: These data show a significant relaxing effect of tamsulosin on the resting urethral tone in healthy females in vivo. These results may suggest tamsulosin as a new pharmacological approach to treat urinary retention due to overactive or non-relaxing urethra in women.

Introduction

Chronic urinary retention in young women as a part of a syndrome associated with polycystic ovaries has been described in 1988 by Fowler et al. [1]. Women affected by chronic urinary retention usually present with impaired detrusor contractility, bladder outflow obstruction or even with a combination of both problems. Since an abnormal electromyographic activity in the external urethral sphincter has been found, a functional bladder outflow obstruction by a non-relaxing or overactive sphincter mechanism is thought to be the underlying reason [2].

In these women treatment modalities basically rely on the intermittent self catheterisation, however the goal in these patients would be to restore voluntary voiding with tolerable amounts of residual urine. Sacral neuromodulation has been tried and was found to be effective to restore the ability to void voluntarily in many patients [3]. Although the injection of botulinum toxin into the external urethral sphincter has been shown to improve the ability to void in some women with urinary retention [4], a study in women with abnormal sphincter electromyography did not show a symptomatic benefit [5].

Only one study tried α-blockers in chronic urinary retention with some success [6], however a pharmacological treatment option to close the gap between catheterisation and invasive procedures would be of value for this patient population. There is now a considerable amount of experimental data from animal and human studies to show that α-blocking agents have the capacity to relax the urethral tone. The aim of this functional urodynamic experiment was to study the effect of the selective α1A-blocker tamsulosin on the urethral pressure in healthy human females and assessed first the resting urethral pressure and second the urethral contractility in response to magnetic stimulation of the sacral roots.

Section snippets

Subjects and methods

The experimental protocol was approved by the local ethics committee. 11 healthy female subjects (mean age 24 years, range 20–29 years) gave a written informed consent and were included in the study. None of the subjects had a history of recurrent urinary tract infections, stress or urge urinary incontinence or was taking any medication known to influence the lower urinary tract. Immediately before and two days after the experiment, urine screening tests were done to exclude urinary tract

Results

The experimental procedure was well tolerated by all studied subjects. Each the baseline and the follow-up measurements took around 30 minutes to perform. Urine screening tests were all normal before as well as two days after the experiment. None of the subjects felt any pain or discomfort during single pulse magnetic stimulation. 4 out of the 11 studied subjects reported a light tiredness at the follow-up 6 hours after tamsulosin intake.

Discussion

To our knowledge this is the first urodynamic controlled study to show that the selective α1A-antagonist tamsulosin has a significant relaxing effect on the urethral tone in healthy females in vivo. Our data show clearly that the resting tone of the female urethra is lowered significantly while the contractility in response to as sacral magnetic stimulation is not influenced by the drug. The relaxing effect of tamsulosin on the urethra was significant in terms of mean urethral pressure and

Conclusion

These data show a significant relaxing effect of tamsulosin on the resting urethral tone in healthy females in vivo. These results may suggest tamsulosin as a new pharmacological approach to treat urinary retention due to overactive or non-relaxing urethra in women.
Editorial Comment

C. Chapple, Sheffield, United Kingdom

[email protected]

This study has evaluated the effect of tamsulosin on urethral pressure in 11 young asymptomatic females. It is clear that tamsulosin reduced the mean

Acknowledgements

The authors are grateful to Ms. Nicole Honegger for excellent technical assistance and Mr. Huub van Hedel for statistical counselling. This study was supported by the Swiss National Foundation (Grant No. 32.52562.97), the European Community (Grant REBEC QLG5-CT-2001-00822) and a research grant from Boehringer Ingelheim.

References (28)

  • H Lepor

    Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group

    Urology

    (1998)
  • P Abrams et al.

    Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury

    J. Urol.

    (2003)
  • C.J Fowler et al.

    Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome?

    BMJ

    (1988)
  • M.J Swinn et al.

    Sacral neuromodulation for women with Fowler’s syndrome

    Eur. Urol.

    (2000)
  • Cited by (43)

    • Tamsulosin vs placebo to prevent postoperative urinary retention following female pelvic reconstructive surgery: a multicenter randomized controlled trial

      2021, American Journal of Obstetrics and Gynecology
      Citation Excerpt :

      However, they do highlight that alpha receptor antagonists are a potentially useful and understudied therapeutic option to prevent POUR in women. Furthermore, the alpha receptor antagonist tamsulosin has been shown to decrease postvoid residual (PVR), increase peak urinary flow rate, decrease urethral pressures, and improve bothersome lower urinary tract symptoms (LUTS) in women, demonstrating that it is efficacious in both genders19–22 Although the etiology of POUR after female pelvic reconstructive surgery is multifactorial, it likely involves impaired relaxation of the bladder outlet to a large degree.

    • Adrenoceptors in the Lower Urinary Tract

      2023, Handbook of Experimental Pharmacology
    • Drug Treatment of Lower Urinary Tract Dysfunction in Women

      2023, Textbook of Female Urology and Urogynecology: Clinical Perspectives
    View all citing articles on Scopus
    View full text